Patients must have histologically confirmed unresectable stage IV RCC with a clear cell component; have received at least two prior systemic regimens (both an anti-PD-1/PD-L1 monoclonal antibody and a VEGF receptor-targeted TKI, in sequence or in combination); have measurable disease per RECIST v1.1 by blinded independent central review (BICR); have a Karnofsky Performance Status (KPS) score of ≥70%; and have radiographic disease progression on or after the most recent regimen per investigator (60). The gene discussed is PDCD1; the disease is renal cell carcinoma.